Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Wakamoto Pharmaceutical CoTSE:4512 +1.86%62 3-Year ROIIC % is 6.17 as of Mar. 2026, which is 4% above its 10-year median of 5.91. GuruFocus rates TSE:4512 with a GF Score™ of 62/100 and a GF Value™ of 円319.46 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 947 Drug Manufacturers companies, Wakamoto Pharmaceutical Co ranks better than 53.85% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Wakamoto Pharmaceutical Co's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was 6.17%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Wakamoto Pharmaceutical Co's 3-Year ROIIC % or its related term are showing as below:
TSE:4512's 3-Year ROIIC % is ranked better than 53.85% of 947
companies
in the Drug Manufacturers industry
Industry Median: 3.7
vs TSE:4512: 6.17
Wakamoto Pharmaceutical Co (TSE:4512) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Wakamoto Pharmaceutical Co 3-Year ROIIC % Related Terms
Wakamoto Pharmaceutical Co 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Wakamoto Pharmaceutical Co's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wakamoto Pharmaceutical Co 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Wakamoto Pharmaceutical Co's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Wakamoto Pharmaceutical Co's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Wakamoto Pharmaceutical Co (TSE:4512) has a 3-Year ROIIC % of 6.17 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Wakamoto Pharmaceutical Co and its competitors. This is near median its historical median of 5.91. According to the industry distribution chart, Wakamoto Pharmaceutical Co ranks #437 out of 947 companies in the Drug Manufacturers industry, placing it in the top 46.1%.
Is Wakamoto Pharmaceutical Co's 3-Year ROIIC % too high?
Wakamoto Pharmaceutical Co's current 3-Year ROIIC % of 6.17 is near median its 10-year median of 5.91. The Drug Manufacturers industry median 3-Year ROIIC % is 3.70. Wakamoto Pharmaceutical Co's value of 6.17 is 66.8% above this industry median. Based on the distribution chart, Wakamoto Pharmaceutical Co ranks #437 out of 947 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Wakamoto Pharmaceutical Co has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Wakamoto Pharmaceutical Co's 3-Year ROIIC % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Wakamoto Pharmaceutical Co ranks #437 out of 947 companies for 3-Year ROIIC %. This puts Wakamoto Pharmaceutical Co in the upper half of its industry. The industry median 3-Year ROIIC % is 3.70. Wakamoto Pharmaceutical Co's value of 6.17 is 66.8% above this benchmark. While the company's 10-year median is 5.91 vs. the industry median of 3.70, Wakamoto Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.70, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wakamoto Pharmaceutical Co's current 3-Year ROIIC % of 6.17 is 66.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Wakamoto Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wakamoto Pharmaceutical Co's current 3-Year ROIIC % is 6.17, which is near median its own 10-year median of 5.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wakamoto Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Wakamoto Pharmaceutical Co (TSE:4512) is currently considered Modestly Undervalued. The stock's GF Value™ is 円319.46, compared to a current price of 円274.00 — trading 14.2% below its estimated fair value. The current 3-Year ROIIC % is 6.17, which is near median its 10-year median of 5.91 and 66.8% above the Drug Manufacturers industry median of 3.70. Wakamoto Pharmaceutical Co's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Wakamoto Pharmaceutical Co (TSE:4512), the current 3-Year ROIIC % is 6.17 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wakamoto Pharmaceutical Co (TSE:4512) Overvalued in 2026?
Based on GuruFocus' analysis, Wakamoto Pharmaceutical Co stock appears to be undervalued.
The current stock price of 円274.00 is trading 14.2% below its estimated GF Value™ of 円319.46.
GuruFocus considers Wakamoto Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for TSE:4512:
3-Year ROIIC %: 6.17 (near median its 10-year median of 5.91)
GF Value™: 円319.46 vs. price of 円274.00 (14.2% below fair value)
Industry Position: 66.8% above the Drug Manufacturers median (#437 of 947)
No single metric tells the full story. See the TSE:4512 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wakamoto Pharmaceutical Co Ltd is the pharmaceutical company based in Japan. It is engaged in the research and development, production and sale of ethical drugs and non-prescription drugs. The company specializes in therapeutic and diagnostic agents for ophthalmic disorders. It offers Strong Wakamoto, a gastrointestinal drug for digestion, the intestinal function controlling, and nutritional supply.
62GF Score
Get the complete analysis for TSE:4512
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4512 has been successfully added to your 
